Azithromycin resistance and decreased ceftriaxone susceptibility in Neisseria gonorrhoeae, Hawaii, USA

Emerging Infectious Diseases

Volumn 23, Issue 5, 2017, Pages 830-832

  Papp, John R ^a   Abrams, A Jeanine ^a   Nash, Evelyn ^a   Katz, Alan R ^b,c   Kirkcaldy, Robert D ^a   O’Connor, Norman P ^c   O’Brien, Pamela S ^c   Harauchi, Derek H ^c   Maningas, Eloisa V ^c   Soge, Olusegun O ^d   Kersh, Ellen N ^a   Komeya, Alan ^b   Tomas, Juval E ^b   Wasserman, Glenn M ^b,c   Kunimoto, Gail Y ^c   Trees, David L ^a   Whelen, A Christian ^b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c Hawaii Department of Health   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; MACROLIDE; RNA 23S; ANTIINFECTIVE AGENT;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; EPSILOMETER TEST; GENE MUTATION; GENOME ANALYSIS; GONORRHEA; HAWAII; MINIMUM INHIBITORY CONCENTRATION; MTRR GENE; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; NEISSERIA GONORRHOEAE; NONHUMAN; NUCLEOTIDE SEQUENCE; PENA GENE; PHYLOGENETIC TREE; PHYLOGENY; PONA GENE; SEXUAL TRANSMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE GENOME SEQUENCING; BACTERIAL GENOME; CLASSIFICATION; DRUG EFFECTS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFTRIAXONE; DRUG RESISTANCE, BACTERIAL; GENOME, BACTERIAL; GONORRHEA; HAWAII; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; NEISSERIA GONORRHOEAE; PHYLOGENY; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

EID: 85018630020     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2305.170088     Document Type: Article

References (15)

1. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27:587–613. http://dx.doi.org/10.1128/CMR.00010-14
2. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [cited 2016 Dec 22]. http://www.cdc.gov/std/tg2015
3. Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project Protocol [cited 2016 Dec 22]. http://www.cdc.gov/std/gisp2014/gisp-2014-text-fig-tables.pdf
4. Kirkcaldy RD, Harvey A, Papp JR, Del Rio C, Soge OO, Holmes KK, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance—the Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ. 2016;65:1–19. http://dx.doi.org/10.15585/mmwr.ss6507a1
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement (M100–S25). Wayne (PA): The Institute; 2015.
6. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56:1273–80. http://dx.doi.org/10.1128/AAC.05760-11
7. Cousin SL Jr, Whittington WL, Roberts MC. Acquired macrolide resistance genes and the 1 bp deletion in the mtrR promoter in Neisseria gonorrhoeae. J Antimicrob Chemother. 2003;51:131–3. http://dx.doi.org/10.1093/jac/dkg040
8. Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother. 2010;54:3812–6. http://dx.doi.org/10.1128/AAC.00309-10
9. Lindberg R, Fredlund H, Nicholas R, Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother. 2007;51:2117–22. http://dx.doi.org/10.1128/AAC.01604-06
10. Katz AR, Komeya AY, Soge OO, Kiaha MI, Lee MVC, Wasserman GM, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis. 2012;54:841–3. http://dx.doi.org/10.1093/cid/cir929
11. Chisholm SA, Wilson J, Alexander S, Tripodo F, Al-Shahib A, Schaefer U, et al. An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England. Sex Transm Infect. 2016;92:365–7. http://dx.doi.org/10.1136/sextrans-2015-052312
12. Unemo M, Golparian D, Hellmark B. First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea? Antimicrob Agents Chemother. 2014;58:624–5. http://dx.doi.org/10.1128/AAC.02093-13
13. Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med. 2016;374:2504–6. http://dx.doi.org/10.1056/NEJMc1512757
14. Public Health England. GRASP 2013 report: the Gonococcal Resistance to Antimicrobial Surveillance Programme (England and Wales) [cited 2016 Dec 22]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/368477/GRASP_ Report_2013.pdf
15. Lahra MM; Australian Gonococcal Surveillance Programme. Australian Gonococcal Surveillance Programme annual report, 2013. Commun Dis Intell Q Rep. 2015;39:E137–45.